Physician profile
Mary C Trusilo
NPI 1932350220
$4,901.20
in general payments reported to CMS, 2019-2025
23 companies · $1,072 in 2025
The $1,072 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $519 · 2020: $130 · 2021: $559 · 2022: $799 · 2023: $753 · 2024: $1,069 · 2025: $1,072.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,894.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,893.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,149.12 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Intracept |
| Vertos Medical, INC. | $569.17 | 2019-2023 | Mild Device Kit |
| Abbott Laboratories | $482.61 | 2023-2025 | Eterna, Proclaim |
| Relievant Medsystems, INC. | $315.14 | 2022-2023 | Intracept |
| Medtronic, INC. | $253.75 | 2022-2025 | Inceptiv |
| Stryker Corporation | $225.50 | 2024-2025 | Mild Device Kit |
| Spr Therapeutics, INC | $223.08 | 2022-2025 | Sprint Pns System |
| Saluda Medical Americas, INC. | $102.57 | 2024 | Evoke |
| Nalu Medical, INC. | $97.87 | 2021-2024 | Nalu Neurostimulation System |
| Collegium Pharmaceutical, INC. | $91.33 | 2019-2025 | Xtampza, Belbuca |
| Globus Medical, INC. | $56.35 | 2025 | Senza |
| Scilex Pharmaceuticals INC. | $53.53 | 2019 | |
| Lilly USA, LLC | $47.68 | 2023 | Emgality, Reyvow |
| Vertiflex, INC. | $41.85 | 2019 | |
| Nevro Corp. | $39.82 | 2021-2024 | Senza |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $31.54 | 2023 | Ubrelvy |
| Amgen INC. | $24.08 | 2019 | |
| Pfizer INC. | $21.89 | 2024 | |
| Xeris Pharmaceuticals, INC. | $17.42 | 2023 | Gvoke Hypopen |
| Ibsa Pharma INC. | $16.73 | 2025 | Licart, Flector, Tirosint |
| Stimwave Technologies Incorporated | $14.88 | 2022 | |
| International Rehabilitative Sciences, INC | $13.87 | 2023 | Rs 4i Plus Sequential Stimulator |
| Daiichi Sankyo INC. | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Trusilo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.